Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Clover Health Investments Shows Why It Often Pays to Redeem SPAC Shares

By Will Ashworth, InvestorPlace Contributor

Clover Health trades well below its original $10 IPO price. Here’s why the shareholders who redeemed their CLOV stock are ahead of the game.  

10 Shy Blue-Chip Stocks That Deserve the Spotlight

By Will Ashworth, InvestorPlace Contributor

If you’re looking for shy blue-chip stocks to buy, here are 10 with lower-than-average trading volumes to get you on your way. 

It’s Time to Send Out an SOS for the Battered Crypto Miner

By Will Ashworth, InvestorPlace Contributor

Short sellers have made accusations about SOS Limited in recent weeks. It will be hard for investors to trust SOS stock as a result. 

The Odds of Pershing Square Finding a Target Rise by the Day

By Will Ashworth, InvestorPlace Contributor

It’s been eight months since Bill Ackman raised $4 billion. Until he announces a target, PSTH stock won’t be going anywhere but sideways. 

Zomedica’s Early Launch Is Music to Shareholders’ Ears

By Will Ashworth, InvestorPlace Contributor

Zomedica launched its Truforma point-of-care diagnostic platform March 16, ahead of schedule. That’s excellent news if you own ZOM stock.

Infused Beverages Pour on the Potential Gains for Aphria Stock Investors

By Will Ashworth, InvestorPlace Contributor

Aphria CEO Irwin Simon continues to like cannabis-infused drinks, which makes APHA stock one of the top global cannabis plays you can make.

By Donating Coupang Stock to His Foundation, Bill Ackman Wins Twice

By Will Ashworth, InvestorPlace Contributor

Bill Ackman donated more than $1 billion in Coupang shares to charity. Up 44% since its IPO, does his gift make CPNG stock a buy?

Buy Northern Dynasty Minerals Stock If You Have Cash to Lose

By Will Ashworth, InvestorPlace Contributor

Northern Dynasty Minerals got a boost when the U.S. Army Corps of Engineers accepted its appeal request. NAK stock is still in the game.

7 Safe Stocks That Won’t Bleed Your Portfolio

By Will Ashworth, InvestorPlace Contributor

If you’re a risk-averse investor who doesn’t like a lot of volatility, here are seven safe stocks to buy that won’t bleed your portfolio.  

Microvision Isn’t the Second Coming

By Will Ashworth, InvestorPlace Contributor

Microvision has seen MVIS stock gain more than 10,000% over the past year. Now trading above $17, I’m left wondering why?

Load More